Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633773 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTALDH1A1LMNA | |
| SCHEMBL1783805 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTALDH1A1LMNA | |
| SCHEMBL5862217 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTALDH1A1LMNA | |
| SCHEMBL28859554 | 0.93 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4044107 | 0.91 | CTSK (0.49) | CTSKCTSSMAPTALDH1A1LMNA | |
| SCHEMBL348500 | 0.88 | CTSK (0.54) | CTSKCTSSMAPTNPSR1MEN1 | |
| SCHEMBL46367 | 0.88 | CTSK (0.54) | CTSKCTSSMAPTNPSR1MEN1 | |
| SCHEMBL348499 | 0.88 | CTSK (0.54) | CTSKCTSSMAPTNPSR1MEN1 | |
| SCHEMBL1274264 | 0.88 | TSHR (0.51) | CTSKCTSSMAPTALDH1A1LMNA | |
| SCHEMBL13929424 | 0.88 | TSHR (0.51) | CTSKCTSSMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085560-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085564-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2014173375-A1 | A PROCESS FOR THE SYNTHESIS OF MARAVIROC | ZENTIVA, K.S. (CZ) | 2014-10-30 | — | — | WO | disclosed |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7932235-B2 | N-{3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; with deuterium isotop; chemokine (C-C motif) CCR5 receptor antagonist; antiinflammatory agent, viricide; with other active ingredients; HIV, AIDS, multiple sclerosis | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1140085-B1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PHIVCO UK LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| EP-2121676-A1 | PREPERATION AND UTILITY OF CCR5 INHIBITORS | Auspex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1809657-A1 | CYCLIC NONAPEPTIDE AMIDES | AiCuris GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2006048156-A1 | CYCLIC NONAPEPTIDE AMIDES | AICURIS GMBH & CO. KG (DE) | 2006-05-11 | — | — | WO | disclosed |
| CN-1331591-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| EP-0866705-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5852045-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0866705-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | CCR5, CCR8, CCL5 | CTSK 2274/4885CTSS 1684/4885MAPT 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.